Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics, Inc. (SRPT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86B | $1.79B | $1.14B | $843.8M | $612.4M | $455.9M | $380.8M | $301.0M | $154.6M | $5.4M | $1.3M | $9.8M | — | — | — | — | — |
| Research & development | $1.52B | $804.5M | $877.4M | $877.1M | $771.2M | $722.3M | $560.9M | $401.8M | $166.7M | $188.3M | $146.4M | $94.2M | $72.9M | $52.4M | $66.9M | $36.0M | $24.4M |
| Operating expenses | — | — | — | — | — | — | — | — | — | — | $221.4M | $143.5M | $104.5M | $67.0M | — | — | — |
| Operating income | −$699.8M | $218.1M | −$267.8M | −$536.2M | −$459.7M | −$564.2M | −$705.6M | −$343.6M | −$171.6M | −$266.7M | −$220.2M | −$133.8M | −$90.3M | −$29.7M | −$35.9M | −$20.9M | −$15.5M |
| EBITDAderived | −$655.3M | $255.8M | −$223.4M | −$494.3M | −$421.7M | −$537.3M | −$681.1M | −$331.4M | −$163.5M | −$261.1M | −$214.9M | −$130.1M | −$89.0M | −$28.2M | −$34.6M | −$19.5M | −$14.1M |
| Net income | −$713.4M | $235.2M | −$536.0M | −$703.5M | −$418.8M | −$554.1M | −$715.1M | −$361.9M | −$50.7M | −$267.3M | −$220.0M | −$135.8M | −$112.0M | −$121.3M | −$2.3M | −$32.2M | −$25.2M |
| Basic EPSper diluted share | -$7.13 | $2.47 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | -$9.71 | -$5.46 | -$0.86 | -$5.49 | -$5.20 | -$3.39 | -$3.31 | -$5.14 | -$0.02 | -$0.29 | -$0.27 |
| Diluted EPSper diluted share | -$7.13 | $2.34 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | -$9.71 | -$5.46 | -$0.86 | -$5.49 | -$5.20 | -$3.39 | -$3.31 | -$5.14 | -$0.02 | -$0.29 | -$0.27 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 12, 2026Form 4 | Mayo StephenDirector | SellCommon Stock | 7.2K | $17.02 | $123.2K | 1.8K |
| Dec 16, 2025Form 4 | Estepan Ian MichaelChief Operating Officer | SellCommon Stock | 13.2K | $22.31 | $294.2K | 193.3K |
| Mar 12, 2025Form 4 | Nicaise ClaudeDirector | SellCommon Stock | 2.5K | $99.64 | $248.2K | 27.8K |
| Dec 12, 2024Form 4 | Wigzell Hans Lennart RudolfDirector | SellCommon Stock | 10.5K | $124.84 | $1.31M | 22.8K |
| Dec 5, 2024Form 4 | Boor Kathryn JeanDirector | SellCommon Stock | 1.6K | $125.55 | $205.4K | 5.9K |